Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Athersys
Companies To Watch: Athersys Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.  Continue Reading...
  • Lysogene: Mother of Invention
    Lysogene: Mother of Invention

    Karen Aiach had no background in healthcare when her young daughter received a diagnosis of a rare form of Sanfilippo syndrome. Aiach built her company, Lysogene, to create the world’s first treatment for the terrible disease.

  • ARM Extends Its Reach
    ARM Extends Its Reach

    The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.

  • Apellis Advances On Autoimmunity
    Apellis Advances On Autoimmunity

    The unusual story of how Apellis was formed and what led it to target C3, the central factor in the innate-immunity complement system, to treat autoimmune diseases — starting with the ultra-rare blood condition, PNH.

  • Bayer Corrals U.S. Bio Clusters On Both Coasts
    Bayer Corrals U.S. Bio Clusters On Both Coasts

    The heads of the East and West Coast Innovation Centers for Bayer Healthcare discuss their parallel missions, therapeutic areas of focus, and dealmaking models.

  • Companies To Watch: Symbiotix Biotherapies
    Companies To Watch: Symbiotix Biotherapies

    Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical-stage development of its lead compound for treating MS and IBD.

  • Companies To Watch: United Neuroscience
    Companies To Watch: United Neuroscience

    “We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”

  • Our Annual Cancer Immuno-oncology Update 2018
    Our Annual Cancer Immuno-oncology Update 2018

    This year’s IO update is more compact because the essential story has contracted. The odds of success have shifted dramatically and disparately among the various players — all due to Merck’s Keytruda.

  • Companies To Watch: Acceleron
    Companies To Watch: Acceleron

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).

  • Fibrocell: Where Gene Therapy Meets Synthetic Biology
    Fibrocell: Where Gene Therapy Meets Synthetic Biology

    “We had to decide whether to spend a lot of money to bring on a sales force and marketing team, and expand manufacturing to meet demand, or take our resources and refocus them on these rare disorders.”  

  • Alexis Howerton On Starting Up From New Science
    Alexis Howerton On Starting Up From New Science

    Alexis Howerton is a first-time pharma CEO who saw potential in an older drug class that had failed in its targeted indications. She then jumped feet first into obtaining the ideal candidate compound and starting a company to develop it.

  • Aurinia: Teamwork Twice
    Aurinia: Teamwork Twice

    From founding the company to funding it, the CEO of Aurinia Pharmaceuticals explains the genesis of the company and why he left retirement to return to guide the company.

  • Chris Garabedian On How To Drive Drug Development
    Chris Garabedian On How To Drive Drug Development

    Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.

  • Companies To Watch: Sensorion
    Companies To Watch: Sensorion

    This French company is addressing vertigo and hearing loss inside the inner ear.

  • Industry Explorers Blaze On: Vicki Sato — The Biology Biz
    Industry Explorers Blaze On: Vicki Sato — The Biology Biz

    Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.